Oxford, United Kingdom
Barinthus Biotherapeutics, founded in 2016, is a United Kingdom-based clinical-stage biopharmaceutical company that is innovating in the realms of Biotechnology, Health and Wellness, and Pharmaceutical industries. The company specializes in developing novel T-cell immunotherapeutic candidates aimed specifically at tackling chronic infectious diseases, autoimmunity, and cancer.
Centered around its slogan, "Barinthus is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic candidates.", the company leverages four proprietary platform technologies: ChAdOx, MVA, SNAP-TI, and SNAP-CI. Their pipeline includes five diverse product candidates such as VTP-300 and VTP-1000, showcasing their extensive expertise and focus on impactful medical challenges.
In its recent acquisition on 01 September 2025, Clywedog Therapeutics invested in Barinthus, positioning the company as a strong candidate for investors seeking growth opportunities in the biopharmaceutical industry.
